Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
P/E Ratio
--
P/B Ratio
2.11
Industry P/E
--
Debt to Equity
0
ROE
-4.87 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-193.21 Mln
EBITDA
$-223.21 Mln
Net Profit
$-212.21 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Hepion Pharmaceuticals (HEPA)
| -98.75 | -38.85 | -97.36 | -99.57 | -93.24 | -82.06 | -78.97 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Hepion Pharmaceuticals (HEPA)
| -85.26 | -46.05 | -73.68 | -47.95 | -59.14 | -72.85 | -90.08 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.68 | 78.84 | -- | -62.96 | |
| 8.54 | 801.08 | -- | -69.5 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.94 | 2,913.32 | -- | -14.59 |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target... multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Address: 399 Thornall Street, Edison, NJ, United States, 08837 Read more
Interim CEO & CFO
Mr. John T. Cavan
Interim CEO & CFO
Mr. John T. Cavan
Headquarters
Edison, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Hepion Pharmaceuticals Inc (HEPA) stood at $ 3 Mln as on 31-Mar-25
The share price of Hepion Pharmaceuticals Inc (HEPA) is $0.29 (NASDAQ) as of 29-Apr-2025 16:22 EDT. Hepion Pharmaceuticals Inc (HEPA) has given a return of -93.24% in the last 3 years.
Hepion Pharmaceuticals Inc (HEPA) has a market capitalisation of $ 3 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Hepion Pharmaceuticals Inc (HEPA) is 2.11 times as on 29-Apr-2025, a 8% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Hepion Pharmaceuticals Inc (HEPA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Hepion Pharmaceuticals Inc (HEPA) and enter the required number of quantities and click on buy to purchase the shares of Hepion Pharmaceuticals Inc (HEPA).
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Address: 399 Thornall Street, Edison, NJ, United States, 08837
The CEO & director of Mr. John T. Cavan. is Hepion Pharmaceuticals Inc (HEPA), and CFO & Sr. VP is Mr. John T. Cavan.
There is no promoter pledging in Hepion Pharmaceuticals Inc (HEPA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
867
|
|
|
290
|
|
|
80
|
|
|
8
|
| Hepion Pharmaceuticals Inc. (HEPA) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Hepion Pharmaceuticals Inc (HEPA) was $0 Mln.
$0.00
(
